Box 1.

Checklist of points to cover with patients.

• Characteristics of available third-line treatments • The importance of personalizing treatment: there are several options for third-line therapy with different characteristics and the choice is influenced by patient characteristics and preferences • Patient expectations on treatment outcomes, in terms of both efficacy (benefit through disease stabilization) and safety • Advantages and disadvantages of each option, including safety and potential side effects • Strategies for management of side effects, including preventive measures • Patient’s role in adhering to treatment and reporting AEs promptly • The association between early occurrence of HFSR and longer OS, as motivation to continue therapy • The importance of close and regular contact with the oncology team, especially in the first few weeks of treatment

AE, adverse event; HFSR, hand–foot skin reaction; OS, overall survival.